IMMUNOTHERAPY- NEW STEP IN THE TREATMENT OF LUNG CANCER

Abstract

Lung cancer was long considered a poorly immunogenic malignancy. However, recent clinical studies revieled new possibilities of immunotherapy in the treatment of lung cancer. Until now, the best characterized and therapeutically relevant have been cytotoxic T- lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein (PD-1). In several randomized studies, PD-1 / PD- L1 (programmed cell death protein ligand) inhibitors have improved in overall survival compared with docetaxel (delivered in the second- line setting) and shows promising results in the treatment of non-small-cell lung cancer.